Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia-Reference-Cited by-同舟云学术

Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia

Published:2013-11 Issue:6 Volume:55 Page:1332-1336
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Klisovic Rebecca B.,Blum William,Liu Zhongfa,Xie Zhiliang,Kefauver Cheryl,Huynh Lenguyen,Zwiebel James A.,Devine Steven M.,Byrd John C.,Grever Michael R.,Chan Kenneth K.,Marcucci Guido

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2013.838764

Reference29 articles.

1. Cellular Uptake and Intracellular Levels of the Bcl-2 Antisense G3139 in Cultured Cells and Treated Patients with Acute Myeloid Leukemia

2. Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group

3. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia

4. Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antisense Oligonucleotide-Mediated Splice Switching: Potential Therapeutic Approach for Cancer Mitigation;Cancers;2021-11-05

2. Inhibiting RRM2 to enhance the anticancer activity of chemotherapy;Biomedicine & Pharmacotherapy;2021-01

3. Advances in treatment formulations for acute myeloid leukemia;Drug Discovery Today;2018-12

4. Small RNA-mediated prevention, diagnosis and therapies of cancer;Design of Nanostructures for Theranostics Applications;2018

5. RNA-targeted therapeutics in cancer clinical trials: Current status and future directions;Cancer Treatment Reviews;2016-11